Vortioxetine: A Potential Drug for Repurposing for Glioblastoma Treatment via a Microsphere Local Delivery System
ACS Biomaterials Science & Engineering · 14.04.2025 · 11 (4) · 2203-2215
DOI: 10.1021/acsbiomaterials.5c00068 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, online erschienen am 01.04.2025. Verfasst von Yu Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, United Kingdom. Hauptthemen laut MEDLINE: Glioblastoma, Vortioxetine, Microspheres, Drug Repositioning. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Broach Foundation for Brain Cancer Research, Cardiff University.
Abstract (Originalsprache)
Drug repurposing is an attractive route for finding new therapeutics for brain cancers such as glioblastoma. Local administration of drugs to brain tumors or the postsurgical resection cavity holds promise to deliver a high dose to the target site with minimal off-target effects. Drug delivery systems aim to sustain the release of the drug at the target site but typically exhibit drawbacks such as a poor safety profile, uncontrolled/rapid drug release, or poor control over synthesis parameters/material dimensions. Herein, we analyzed the antidepressant vortioxetine and showed in vitro that it causes a greater loss of viability in glioblastoma cells than it does to normal primary human astrocytes. We developed a new droplet microfluidic-based emulsion method to reproducibly produce vortioxetine-loaded poly(lactic-co-glycolic) acid (PLGA) microspheres with tight size control (36.80 ± 1.96 μm). The drug loading efficiency was around 90% when 9.1% (w/w) drug was loaded into the microspheres, and drug release could be sustained for three to 4 weeks. The vortioxetine microspheres showed robust antiglioblastoma efficacy in both 2D monolayer and 3D spheroid patient-derived glioblastoma cells, highlighting the potential of combining an antidepressant with sustained local delivery as a new therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, United Kingdom.
- Cardiff University School of Biosciences, European Cancer Stem Cell Research Institute, Cardiff CF24 4HQ, United Kingdom.
- Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich 8091, Switzerland.
ORCID-Profile: Ben Newland
Förderung
- Medical Research Council
- Broach Foundation for Brain Cancer Research
- Cardiff University
- China Scholarship Council
Zitieren
APA
Wang, Y., Siebzehnrubl, D., Weller, M., Weiss, T., Siebzehnrubl, F. A., & Newland, B. (2025). Vortioxetine: A Potential Drug for Repurposing for Glioblastoma Treatment via a Microsphere Local Delivery System. ACS Biomaterials Science & Engineering, 11(4), 2203-2215. https://doi.org/10.1021/acsbiomaterials.5c00068
Vancouver
Wang Y, Siebzehnrubl D, Weller M, Weiss T, Siebzehnrubl FA, Newland B. Vortioxetine: A Potential Drug for Repurposing for Glioblastoma Treatment via a Microsphere Local Delivery System. ACS Biomaterials Science & Engineering. 2025;11(4):2203-2215. doi:10.1021/acsbiomaterials.5c00068
BibTeX
@article{Wang2025,
author = {Wang, Yu and Siebzehnrubl, Dorit and Weller, Michael and Weiss, Tobias and Siebzehnrubl, Florian A and Newland, Ben},
title = {Vortioxetine: A Potential Drug for Repurposing for Glioblastoma Treatment via a Microsphere Local Delivery System},
journal = {ACS Biomaterials Science & Engineering},
year = {2025},
volume = {11},
number = {4},
pages = {2203--2215},
doi = {10.1021/acsbiomaterials.5c00068}
}
EUVIMED